Cargando…

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Lung cancer is the leading cause of cancer death in Canada and a significant cause of morbidity for patients and their loved ones. There have been rapid advances in preventing, screening and treating this disease. Here, we present a contemporary review of treatment of non-small cell lung cancer in C...

Descripción completa

Detalles Bibliográficos
Autores principales: Mithoowani, Hamid, Febbraro, Michela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946954/
https://www.ncbi.nlm.nih.gov/pubmed/35323350
http://dx.doi.org/10.3390/curroncol29030150
_version_ 1784674320257122304
author Mithoowani, Hamid
Febbraro, Michela
author_facet Mithoowani, Hamid
Febbraro, Michela
author_sort Mithoowani, Hamid
collection PubMed
description Lung cancer is the leading cause of cancer death in Canada and a significant cause of morbidity for patients and their loved ones. There have been rapid advances in preventing, screening and treating this disease. Here, we present a contemporary review of treatment of non-small cell lung cancer in Canada based on current best practices. The focus of this review is to highlight recent data in screening for lung cancer, management of patients with early and locally-advanced non-small cell lung cancer, as well as management of patients with metastatic disease. There is a special focus on the incorporation of immunotherapy into practice and its associated toxicities.
format Online
Article
Text
id pubmed-8946954
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89469542022-03-25 Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology Mithoowani, Hamid Febbraro, Michela Curr Oncol Review Lung cancer is the leading cause of cancer death in Canada and a significant cause of morbidity for patients and their loved ones. There have been rapid advances in preventing, screening and treating this disease. Here, we present a contemporary review of treatment of non-small cell lung cancer in Canada based on current best practices. The focus of this review is to highlight recent data in screening for lung cancer, management of patients with early and locally-advanced non-small cell lung cancer, as well as management of patients with metastatic disease. There is a special focus on the incorporation of immunotherapy into practice and its associated toxicities. MDPI 2022-03-09 /pmc/articles/PMC8946954/ /pubmed/35323350 http://dx.doi.org/10.3390/curroncol29030150 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mithoowani, Hamid
Febbraro, Michela
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
title Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
title_full Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
title_fullStr Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
title_full_unstemmed Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
title_short Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
title_sort non-small-cell lung cancer in 2022: a review for general practitioners in oncology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946954/
https://www.ncbi.nlm.nih.gov/pubmed/35323350
http://dx.doi.org/10.3390/curroncol29030150
work_keys_str_mv AT mithoowanihamid nonsmallcelllungcancerin2022areviewforgeneralpractitionersinoncology
AT febbraromichela nonsmallcelllungcancerin2022areviewforgeneralpractitionersinoncology